TCGA-DK-AA6R-01A-11R-A42T-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 165.6044678
- os_event
- false
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.550
- G2M_CHECKPOINT+0.550
- INTERFERON_ALPHA_RESPONSE+0.490
- MITOTIC_SPINDLE+0.470
- MYC_TARGETS_V1+0.440
- PROTEIN_SECRETION+0.420
- INTERFERON_GAMMA_RESPONSE+0.360
- IL6_JAK_STAT3_SIGNALING+0.280
- MYC_TARGETS_V2+0.260
- PI3K_AKT_MTOR_SIGNALING+0.250
Top 10 suppressed
- BILE_ACID_METABOLISM-0.270
- XENOBIOTIC_METABOLISM-0.220
- NOTCH_SIGNALING-0.160
- ANGIOGENESIS-0.120
- PANCREAS_BETA_CELLS-0.090
- MYOGENESIS-0.080
- ADIPOGENESIS-0.070
- FATTY_ACID_METABOLISM-0.070
- ALLOGRAFT_REJECTION-0.050
- ANDROGEN_RESPONSE-0.050
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-FD-A3N5-01A-11R-A21D-07 | — | — | 0.877 |
| 2 | SRR650195 | — | — | 0.870 |
| 3 | TCGA-CV-7434-01A-11R-2132-07 | — | — | 0.861 |
| 4 | TCGA-BT-A3PJ-01A-21R-A220-07 | — | — | 0.849 |
| 5 | MNG1210 | — | — | 0.836 |
| 6 | TCGA-G2-A2EJ-01A-11R-A180-07 | — | — | 0.833 |
| 7 | DRR168600 | — | — | 0.825 |
| 8 | TCGA-GC-A3RC-01A-11R-A22U-07 | — | — | 0.821 |
| 9 | TCGA-PQ-A6FI-01A-11R-A31N-07 | — | — | 0.813 |
| 10 | sclc239861_S78.txt | — | cohortSC | 0.812 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 34 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.550 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.550 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.490 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.470 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.440 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.420 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.360 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.280 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.260 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.250 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.240 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.230 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.230 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.210 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.210 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.200 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.190 | Temsirolimus | — uncovered |
| MTORC1_SIGNALING | 0.180 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.170 | Temsirolimus | — uncovered |
| APOPTOSIS | 0.170 | Idelalisib | — uncovered |